Shares of Reata Pharmaceuticals were down nearly 40 percent the morning of December 6 after briefing documents released by the U.S. Food and Drug Administration revealed an unflattering opinion of the company’s experimental drug for Alport syndrome, bardoxolone.
If you are not happy with the results below please do another search
50 search results for:
Members of the Sackler family on December 6 said billions of dollars they collected from Purdue Pharma before the company filed for Chapter 11 was the result of extra cash, not part of a “secret plan” to abuse the bankruptcy system.
Future pandemics could be even more lethal than COVID-19 so the lessons learned from the outbreak must not be squandered and the world should ensure it is prepared for the next viral onslaught, one of the creators of the Oxford-AstraZeneca vaccine said.
Merck announced a pause in enrollment for the IMPOWER 22 (MK-8591-022) and IMPOWER 24 (MK-8591-024) Phase 3 clinical studies evaluating investigational, once-monthly, oral islatravir (ISL) – a nucleoside reverse transcriptase translocation inhibitor – for pre-exposure prophylaxis (PrEP) in people at high risk of HIV-1 infection.
Austin, Texas-based Aeglea Biotherapeutics reported what initially appears to be positive outcomes for the company’s Phase III PEACE trial of pegzilarginase in Arginase 1 Deficiency (ARG1-D), a rare, progressive and debilitating disease marked by high levels of the amino acid arginine.
New York City Mayor Bill de Blasio said on December 6 he planned to issue a COVID-19 vaccine mandate for private-sector employers that will go into effect on Dec. 27, calling it a “pre-emptive strike.”
The latest updates from Mesoblast’s Phase III trial on rexlemestrocel-L show that the drug provides the highest benefit when used in patients with certain types of chronic heart failure.
Drugmaker Biohaven Pharmaceutical said on December 6 the company’s intranasal spray to treat migraine showed rapid pain relief and met the main goals in a late-stage study.
Novartis hopes to still play a role in the development of Covid-19 treatments with ongoing research for a pill that could work broadly against coronaviruses, not just the one that causes Covid-19, chief executive Vas Narasimhan told Reuters.
The Omicron variant of the coronavirus has spread to about one-third of U.S. states, but the Delta version remains the majority of COVID-19 infections as cases rise nationwide, U.S. health officials said on December 5.